SCHEIN PHARMACEUTICAL MANAGEMENT WILL CONTINUE UNDER DIRECTION of current president, Martin Sperber, following the death of Chairman Jacob Schein on Nov. 4. Schein, who was 49, had been CEO of the company for the past 10 years. His cancer had been diagnosed for over a year-and-a-half, and he was involved in the establishment of the management group to continue operation of the company. Sperber currently heads the corporation's pharmaceutical component, which includes Phoenix-based Steris Laboratories (makers of sterile parenteral, ophthalmic and otic products) and Danbury Pharmacal. In that role Sperber will be chairman of Danbury. William Haddad remains vice chairman of the Carmel, N.Y.-based generic drug manufacturer. Stanley Bergman is president and CEO of Schein's distribution business. Dental, medical and veterinary products manufactured by Schein and brandname companies are handled by the distribution component. * Ownership of the privately-held company remains within the Schein family estate trust. Organization of the family's interest in the company, which constitutes the vast majority of stock, was established in 1982 and provides for continuity of family ownership. The Scheins asked that expressions of sympathy be made in the form of contributions to the Schein Family Memorial Fund, in care of the New York Community Trust, 415 Madison Avenue, New York, NY 10017. The fund was established when the company's founder Henry Schein died in 1987.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
Generative artificial intelligence tools, such as ChatGPT, have “democratized” AI, and contract research organizations are wholeheartedly embracing these tools, given their focus on efficiency, says Stephen Pyke, who chairs the AI committee at the Association of Clinical Research Organizations.
Japan gives world-first approval recommendations to two domestically originated drugs, for insomnia and glaucoma/ocular hypertension.
